Acerus Pharmaceuticals (ASP) has notable insider buying

Acerus Pharmaceuticals (T:ASP)

Stephen Robert Gregory, a Director, acquired 118,000 Common Shares on an indirect ownership basis for registered holder 8197288 Canada Inc. at a price of $0.240 through the public market between September 7th, 2018 and September 10th, 2018. This represents a $28,320 investment into the company's shares and an account share holdings change of 10.9%.

Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause. The Company offers Natesto, which is the testosterone nasal gel in the United States for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The Company offers TEFINA, which is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction. The Company focuses on TriVair Deposition/Dispersion System, which is a unit dose dry powder inhaler and nasal dispersion system.